Pruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis

Atopic dermatitis (AD) is a common highly pruritic chronic inflammatory skin disorder affecting 5–20% of children worldwide, while the prevalence in adults varies from 7 to 10%. Patients with AD experience intense pruritus that could lead to sleep disturbance and impaired quality of life. Here, we a...

Descripción completa

Detalles Bibliográficos
Autores principales: Koumaki, Dimitra, Gregoriou, Stamatios, Evangelou, George, Krasagakis, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054239/
https://www.ncbi.nlm.nih.gov/pubmed/36983094
http://dx.doi.org/10.3390/jcm12062091
Descripción
Sumario:Atopic dermatitis (AD) is a common highly pruritic chronic inflammatory skin disorder affecting 5–20% of children worldwide, while the prevalence in adults varies from 7 to 10%. Patients with AD experience intense pruritus that could lead to sleep disturbance and impaired quality of life. Here, we analyze the pathophysiology of itchiness in AD. We extensively review the histamine-dependent and histamine-independent pruritogens. Several receptors, substance P, secreted molecules, chemokines, and cytokines are involved as mediators in chronic itch. We also, summarize the new emerging antipruritic drugs in atopic dermatitis.

Ejemplares similares